Serum Fatty Acid Binding Protein 4 Concentrations Are Positively and Independently Associated with Blood Pressure and Abdominal Fat among Parameters in Health Check-Ups in Ordinary Middle-Aged Japanese Males

Yamada, Masami; Mochizuki, Kazuki; Honma, Kenji; Miyauchi, Rie; Kasezawa, Nobuhiko; Tohyama, Kazushige; Goda, Toshinao

doi:10.3177/jnsv.61.291

Cited by 7 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 FABP4 functions as a transmitter linking lipid metabolism to inflammation 11 and has been shown to be associated with risk factors of PE, including hypertension, obesity, and diabetes. 12,13 Emerging studies have illustrated that PE patients exhibited elevated levels of FABP4; [14][15][16] however, the mechanism by which FABP4 contributes to the pathogenesis of PE remains uninvestigated. Recently, FABP4 has been reported to regulate NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in macrophages.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A

Chang

Yang²,

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Preeclampsia (PE) is one of the leading causes of maternal death worldwide. Elevated fatty acid binding protein 4 (FABP4) levels have been observed in patients with PE, however, the mechanism by which FABP4 contributes to the pathogenesis of PE remains unclear. In this study, we compared the levels of FABP4 and cytokines between 20 PE patients and 10 healthy pregnant women by using ELISA, immunohistochemistry (IHC) analysis, and flow cytometry (fluorescence-activated cell sorting, FACS). Elevated FABP4 was accompanied by regulatory T (Treg)/T helper type 17 (Th17) imbalance in PE. Knockdown of FABP4 attenuated lipopolysaccharide (LPS)-induced NLR family pyrin domain containing 3 (NLRP3) inflammasome activation and interleukin-17A (IL-17A) production in primary macrophages. In addition, silencing of FABP4 also suppressed Th17 differentiation via paracrine signaling. Overexpression of FABP4 promoted Th17 differentiation via increasing IL-17A/IL-23 release. Reciprocally, IL-17A upregulated FABP4 and activated the NLRP3 inflammasome in vitro and in vivo. The in vivo studies revealed that FABP4 inhibitor BMS309403 ameliorated PE clinical phenotypes, the Treg/Th17 imbalance, and NLRP3 inflammasome activation in PE mice model. In conclusion, FABP4 facilitates inflammasome activation to induce the imbalance of Treg/Th17 in PE via forming a positive feedback with IL-17A.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A

Chang

Yang²,

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…Protection from viral infections in the gut [63,72] Epithelialization, cell polarization, cell movement and rearrangement, neurite outgrowth, synaptic activity in the central nervous system [73] Fatty acid binding Breast cancer cells lines inhibition [74][75][76] Protein (FABP) Association with breast cancer; indicator [77][78][79][80] Cluster of differentiation (CD36) Anticancer properties by interacting with FABP [75] Anti-inflammatory properties [54] Breast cancer susceptibility proteins (BRCA1 and BRCA2) Breast cancer DNA repair process inhibition [81,82] MFGM proteins (complex)…”

Section: Component Health Aspects Referencesmentioning

confidence: 99%

Sources, Production, and Clinical Treatments of Milk Fat Globule Membrane for Infant Nutrition and Well-Being

Fontecha

Brink

et al. 2020

Nutrients

View full text Add to dashboard Cite

Research on milk fat globule membrane (MFGM) is gaining traction. The interest is two-fold; on the one hand, it is a unique trilayer structure with specific secretory function. On the other hand, it is the basis for ingredients with the presence of phospho- and sphingolipids and glycoproteins, which are being used as food ingredients with valuable functionality, in particular, for use as a supplement in infant nutrition. This last application is at the center of this Review, which aims to contribute to understanding MFGM’s function in the proper development of immunity, cognition, and intestinal trophism, in addition to other potential effects such as prevention of diseases including cardiovascular disease, impaired bone turnover and inflammation, skin conditions, and infections as well as age-associated cognitive decline and muscle loss. The phospholipid composition of MFGM from bovine milk is quite like human milk and, although there are some differences due to dairy processing, these do not result in a chemical change. The MFGM ingredients, as used to improve the formulation in different clinical studies, have indeed increased the presence of phospholipids, sphingolipids, glycolipids, and glycoproteins with the resulting benefits of different outcomes (especially immune and cognitive outcomes) with no reported adverse effects. Nevertheless, the precise mechanism(s) of action of MFGM remain to be elucidated and further basic investigation is warranted.

show abstract

“…FABP4 is expressed mainly in adipocytes and can be released into the circulation (6). In the nonpregnant state, FABP4 is associated with the following known pre-eclampsia risk factors: obesity, hypertension, and diabetes (6,7).…”

mentioning

confidence: 99%

Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes

et al. 2016

View full text Add to dashboard Cite

OBJECTIVETo examine the association between fatty acid binding protein 4 (FABP4) and preeclampsia risk in women with type 1 diabetes. RESEARCH DESIGN AND METHODSSerum FABP4 was measured in 710 women from the Diabetes and Pre-eclampsia Intervention Trial (DAPIT) in early pregnancy and in the second trimester (median 14 and 26 weeks' gestation, respectively). RESULTSFABP4 was significantly elevated in early pregnancy (geometric mean 15.8 ng/mL [interquartile range 11.6-21.4] vs. 12.7 ng/mL [interquartile range 9.6-17]; P < 0.001) and the second trimester (18.8 ng/mL [interquartile range 13.6-25.8] vs. 14.6 ng/mL [interquartile range 10.8-19.7]; P < 0.001) in women in whom pre-eclampsia later developed. Elevated second-trimester FABP4 level was independently associated with pre-eclampsia (odds ratio 2.87 [95% CI 1.24-6.68], P = 0.03). The addition of FABP4 to established risk factors significantly improved net reclassification improvement at both time points and integrated discrimination improvement in the second trimester. CONCLUSIONSIncreased second-trimester FABP4 independently predicted pre-eclampsia and significantly improved reclassification and discrimination. FABP4 shows potential as a novel biomarker for pre-eclampsia prediction in women with type 1 diabetes.Pre-eclampsia, defined as new-onset hypertension and proteinuria occurring after 20 weeks of gestation, is associated with significant perinatal morbidity and mortality (1,2). Pre-eclampsia is two to four times more likely to develop in women with type 1 diabetes than in the background population (3,4).Fatty acid binding protein 4 (FABP4), or adipocyte FABP, is an intracellular lipid chaperone involved in coordination of lipid transportation (5). FABP4 is expressed mainly in adipocytes and can be released into the circulation (6). In the nonpregnant state, FABP4 is associated with the following known pre-eclampsia risk factors: obesity, hypertension, and diabetes (6,7).Several studies have reported elevated FABP4 levels in women with pre-eclampsia (8,9) or in those in whom pre-eclampsia later developed (10), compared with those in whom it did not, although all studies excluded women with diabetes.Our objective was to examine the role of FABP4 as a potential biomarker for preeclampsia alone, and in tandem with established clinical risk factors, in women with type 1 diabetes.

show abstract

Serum Fatty Acid Binding Protein 4 Concentrations Are Positively and Independently Associated with Blood Pressure and Abdominal Fat among Parameters in Health Check-Ups in Ordinary Middle-Aged Japanese Males

Cited by 7 publications

References 31 publications

RETRACTED: FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A

RETRACTED: FABP4 facilitates inflammasome activation to induce the Treg/Th17 imbalance in preeclampsia via forming a positive feedback with IL-17A

Sources, Production, and Clinical Treatments of Milk Fat Globule Membrane for Infant Nutrition and Well-Being

Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes

Contact Info

Product

Resources

About